U.S. 503B Compounding Pharmacies Market Size to Hit US$ 2.25 Bn by 2033

U.S. 503B Compounding Pharmacies Market Size & Trends

The U.S. 503B compounding pharmacies market size was estimated at US$ 1.08 billion in 2023 and is projected to grow US$ 2.25 billion by 2033, rising at a compound annual growth rate (CAGR) of 7.63% from 2024 to 2033. The need for 503B compounding pharmacies is growing because of the growing focus on patient safety and adherence to regulations.

Unlock Infinite Advantages: Subscribe to Annual Membership

Industry at a Glance

The FDA directly regulates 503B pharmacies through the use of CGMP regulations, which are the subject of the 503B compounding pharmacies market. Pharmaceutical firms also adhere to the same set of CGMP rules. As a result, a 503B pharmacy is a compounding pharmacy that follows the strict CGMP regulations.

The only pharmacies authorized to provide compounded pharmaceuticals for use in doctor's offices, clinics, and hospitals are these 503B outsourcing facilities. In recent times, the 503B U.S. compounding pharmacy market has undergone significant changes due to a number of key developments that will likely affect 503B outsourcing facilities in 2024 and beyond.

Trends in the U.S. 503B Compounding Pharmacies Market

• 503B compounding pharmacies will continue to place a high priority on quality assurance in the country’s pharmaceutical industry. Ensuring the safety and effectiveness of compounded pharmaceuticals will require the continued implementation of stringent standards, frequent testing, and inspections, as well as the implementation of strong quality control systems.
• It is probable that compounding pharmacies will implement cutting-edge technologies to improve the precision and efficiency of their compounding procedures. Digital platforms, robotic systems, and automation can all be used to increase productivity by optimizing processes, lowering errors, and increasing overall efficiency.
• Compounding pharmacies and healthcare providers such as clinics, hospitals, and doctors, are working together more and more. The purpose of this partnership is to enhance communication between medical experts and guarantee the smooth incorporation of compounded pharmaceuticals into patient care programs.
• Compounding pharmacies may expand their offerings to include more healthcare solutions in addition to standard compounding.

The Role of AI in Compounding Pharmacies

The integration of artificial intelligence (AI) into the 503B compounding pharmacies is poised to significantly enhance market growth. AI's ability to analyze vast datasets quickly and accurately improves quality control and ensures consistent, high-quality compounded medications. By automating routine tasks, AI reduces human error, streamlines operations, and increases efficiency, allowing pharmacists to focus on more complex aspects of compounding.

Predictive analytics powered by AI can forecast demand trends, optimize inventory management, and minimize waste, leading to cost savings and better resource allocation. Moreover, AI-driven systems can assist in regulatory compliance by maintaining meticulous records and ensuring adherence to stringent standards set by the FDA. AI also plays a crucial role in personalized medicine by analyzing patient data to customize formulations, thereby improving patient outcomes.

The integration of AI not only accelerates the compounding process but also enhances the overall safety and effectiveness of medications. As the healthcare industry increasingly embraces technological advancements, AI's role in 503B compounding pharmacies is expected to expand, driving market growth and setting new standards for precision and efficiency in pharmaceutical compounding.

Top Companies in the U.S. 503B Compounding Pharmacies Market

• SCA Pharma
• Revelation Pharma
• Nephron Pharmaceuticals Corporation
• Athenex, Inc.
• Wells Pharma of Houston LLC
• Olympia Pharmacy
• Fagron Compounding Pharmacies

Reduced Drug Costs Drives the U.S. 503B Compounding Pharmacies Market

By decreasing waste and driving down prescription prices, the hospital can actually lower organizational risk through greater regulatory compliance and minimize waste by choosing the right outsourcing pharmacy partner. Furthermore, 503Bs are better suited to comply with the increasingly strict FDA regulations and cGMPs, which benefit the hospital in ways such as extended beyond-use-date of products (beyond that of in-hospital compounded products), which minimize waste, aid in inventory management, and permit the shipment of goods to hospitals located further within the health system than is currently permitted by federal regulations. Even while these benefits come at a higher cost per unit when compared to the cost of buying a sterile vial of medication, the hospital still pays less for these medications.

Personalized Medicines: Market’s Largest Potential

Manufacturing specialized pharmaceuticals is a compounding pharmacy's primary duty. For the purpose of creating pharmaceuticals that are specifically tailored to each patient's needs, they collaborate closely with patients and healthcare professionals. A 50 mg dose or a 100 mg dose, for example, or the actual components can be customized, as can the dosage forms (such as a capsule or syringe) and strength. Compounding pharmacies have a strong position to address the growing demand for specially formulated pharmaceuticals.

What Factors Contribute to the Market’s Growth in United States?

Unites States, being is a center of innovation, home to top pharmaceutical and biopharma businesses as well as medication inventors, holds a great potential for the industry. The industry has a promising future as patients with rare diseases benefit greatly from advancements made possible by technologies like artificial intelligence, biotech, mRNA, and the cell and gene space.

Growth is explained by the existence of major international chains, including Rite Aid Corp., Boots, Walgreens, CVS Health, UnitedHealth Group, Cigna, and Walmart. To increase their dominance and presence, these players are utilizing a variety of techniques and cutting-edge technologies.

The Federal Food, Drug, and Cosmetic Act's Section 503A or 503B applies to drug products or categories of drug products that provide demonstrable difficulties for compounding. This proposed rule was released by the U.S. Food and Drug Administration (FDA) on March 20, 2024.

Recent Developments:

• In July 2024, compounded semaglutide is the active component of medications such as Ozempic® and Wegovy®. For this product, the weight loss telemedicine brand is SHOWW. SHOWW distinguishes itself from other companies in the industry with its FDA-Regulated 503B Pharmacy Compounded Semaglutide due to its extraordinarily high quality. Semaglutide was first administered as an injectable medication to treat diabetes.